CAMBRIDGE, Mass., March 11, 2025 /PRNewswire/ -- Count Me In, a patient-partnered research initiative led by the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute, is launching a new ...
PHOENIX--(BUSINESS WIRE)--Verve Medical, Inc. (Verve) announced today that the Company has received approval from the US Food & Drug Administration (FDA) to initiate its Natural Orifice via renal ...
Genenta Science has announced that 38 patients have been enrolled in its study for newly diagnosed glioblastoma multiforme (GBM), where 25 patients received the treatment Temferon. Two patients have ...
Hosted on MSN
Allogene Therapeutics Presents Promising Phase 1 Data for ALLO-316 in Renal Cell Carcinoma
On June 1, Allogene Therapeutics Inc. (NASDAQ:ALLO) presented updated data from the Phase 1 TRAVERSE study of ALLO-316 in advanced or metastatic renal cell carcinoma/RCC during an oral presentation at ...
(MENAFN- IANS) New Delhi, April 11 (IANS) In a bid to bridge critical gaps in renal healthcare in India, the Adani Group's CSR Initiative on Friday announced a partnership with Adharshila Trust to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback